[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![@zipjet Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::23257566.png) @zipjet zipjet

zipjet posts on X about $ocul, $shak, $tgtx, accounting the most. They currently have XXXXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.

### Engagements: XXX [#](/creator/twitter::23257566/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::23257566/c:line/m:interactions.svg)

- X Week XXXXXX -XX%
- X Month XXXXXXX +85%
- X Months XXXXXXX -XX%
- X Year XXXXXXXXX -XX%

### Mentions: X [#](/creator/twitter::23257566/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::23257566/c:line/m:posts_active.svg)

- X Week XX -XX%
- X Month XXX -XXXX%
- X Months XXX +67%
- X Year XXXXX -XXXX%

### Followers: XXXXX [#](/creator/twitter::23257566/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::23257566/c:line/m:followers.svg)

- X Week XXXXX -XXXX%
- X Month XXXXX +1.10%
- X Months XXXXX +14%
- X Year XXXXX +26%

### CreatorRank: XXXXXXXXX [#](/creator/twitter::23257566/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::23257566/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[stocks](/list/stocks)  XXXX% [cryptocurrencies](/list/cryptocurrencies)  XXXX% [finance](/list/finance)  XXXX% [technology brands](/list/technology-brands)  XXXX%

**Social topic influence**
[$ocul](/topic/$ocul) #12, [$shak](/topic/$shak) 3.23%, [$tgtx](/topic/$tgtx) 3.23%, [accounting](/topic/accounting) 3.23%, [future](/topic/future) 3.23%, [losses](/topic/losses) 3.23%, [$lqda](/topic/$lqda) 3.23%, [$uthr](/topic/$uthr) XXXX%

**Top accounts mentioned or mentioned by**
[@lucy3370](/creator/undefined) [@martychargin](/creator/undefined) [@perryglasenberg](/creator/undefined) [@paperboy2009](/creator/undefined) [@biowreck2022](/creator/undefined) [@lars57360069](/creator/undefined) [@jonahlupton](/creator/undefined) [@commonsenseplay](/creator/undefined) [@safwan22025](/creator/undefined) [@mbamcnulty](/creator/undefined) [@goldriversports](/creator/undefined) [@diyinvestguy](/creator/undefined) [@jeremyfalmouth](/creator/undefined) [@john_hersc79276](/creator/undefined) [@sububoston](/creator/undefined) [@behrooznajafi](/creator/undefined) [@vxeel](/creator/undefined) [@ngyojiw](/creator/undefined) [@svix_enjoyoor](/creator/undefined) [@paperhands91](/creator/undefined)

**Top assets mentioned**
[Ocular Therapeutix, Inc. (OCUL)](/topic/$ocul) [Shakita Inu (SHAK)](/topic/$shak) [TG Therapeutics, Inc. (TGTX)](/topic/$tgtx) [Liquidia Corporation Common Stock (LQDA)](/topic/$lqda) [United Therapeutics, Corp. (UTHR)](/topic/$uthr)
### Top Social Posts
Top posts by engagements in the last XX hours

"@JonahLupton @commonsenseplay $SHAK is worthless IMO. Ate there once. Never again"  
[X Link](https://x.com/zipjet/status/1997834001332244656)  2025-12-08T01:01Z 2922 followers, XXX engagements


"@safwan22025 $TGTX Those earnings are really an accounting artifact. There were no sales to support the vast majority of those EPS no cash flows. Those earnings are essentially a recognition that the prior losses will shelter future earnings"  
[X Link](https://x.com/zipjet/status/1998036512580260138)  2025-12-08T14:26Z 2923 followers, XXX engagements


"@diyinvestguy Not a hedge. But a reasonable pair trade is long $LQDA and short $UTHR. I think finding the XXX patent invalid would see UTHR drop 50-100 points"  
[X Link](https://x.com/zipjet/status/1997837847848726732)  2025-12-08T01:17Z 2921 followers, 1202 engagements


"$OCUL 📰 Summary: Ocular Therapeutix Accelerates Plans for Wet AMD Drug AXPAXLI Ocular Therapeutix Inc. has announced it now intends to submit a New Drug Application (NDA) for AXPAXLI (OTX-TKI) for the treatment of wet age-related macular degeneration (wet AMD) following positive year-one data from its ongoing SOL-1 Phase X clinical trial. Key Points: Accelerated Submission: The decision to potentially submit the NDA after only the first year of data is based on recent public statements from FDA leadership regarding the potential for a single registrational trial for new product candidates as"  
[X Link](https://x.com/zipjet/status/1998007990557835683)  2025-12-08T12:33Z 2922 followers, XXX engagements


"$OCUL We all get some right and some wrong. Some friends told me they wanted to sell OCUL. I told them I thought it would be over XX by the end of this year. They sold at $8.35"  
[X Link](https://x.com/zipjet/status/1998039262227468379)  2025-12-08T14:37Z 2922 followers, 1445 engagements